TickerTalks
Browse all tickers →
TickerTalks›$NEO
NENEO

NeoGenomics, Inc.

$NEO·$497M·Medical - Diagnostics & Research·Healthcare
$18.74-2.9%YTD+57.7%1Y+141.2%
Price updated 2h ago·X counts updated 2d ago
NENEO
$NEONeoGenomics, Inc.
$18.74-2.85%1.7k posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $NEO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

1,744X posts · last 7 days
Sep 11Sep 27
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $NEO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-09-29

NEO holders are cautiously bullish on the Humanless Blockchain narrative — Neo X is live with AI agents making autonomous micro-transactions via x402 payments, and a live gamified showcase invites competitive AI agent use. Bulls frame NEO's original smart-economy thesis as relevant again in the AI-agent era; no bear voice in the window.

Read what X is saying about $NEO

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NEO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-28

The move is getting stronger, with heavier trading behind it.

NeoGenomics is a cancer-genomics testing lab quietly compounding — up 145% in a year on real revenue and MRD momentum, and the X chatter on file is about the wrong asset.

NeoGenomics is a cancer-genomics testing lab — next-generation-sequencing testing for solid tumors, minimal-residual-disease (MRD) assays, and a growing data-plus-AI overlay. It's up 145% in a year on execution beats and rising expectations for the MRD pipeline.

  • The trajectory is real: last quarter revenue printed ~$202M with a small EPS beat, and analysts see revenue moving from ~$804M this year to over $965M by 2028 as the MRD test menu expands and NGS volumes scale.
  • The financials still aren't clean: operating margin sits at -8.6% with net income negative — the model needs volume-driven operating leverage on the existing lab footprint to inflect the P&L.
  • The stock is at ~94% of the 52-week range with modest volume — no hot money is driving this; it's incremental institutional buyers building a position as the MRD story develops.

October 27 earnings and any color on MRD test-menu launch cadence is the near-term unlock; a re-affirmed 8-10% top-line growth with margin expansion extends the tape, a soft NGS or MRD-adoption print is what stalls it near the highs.

What to watch: October 27 earnings — a re-affirmed 8-10% top-line growth with visible margin expansion and MRD test-menu color extends the tape near highs; a soft NGS or MRD-adoption print is what stalls the run.

On the calendar: 2026-10-27 — Q3 earnings

sentiment wrong asset

Read the AI verdict on $NEO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Cancer genetics testing laboratory providing molecular diagnostics, genomic profiling, and pathology services to oncologists nationwide.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $NEO.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $NEO

Partial — Cancer genetics testing laboratory providing molecular diagnostics, genomic profiling, and pathology services to oncologists nationwide.

Industry benchmark

18-name peer basket
+44.4%YTD
+74.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-7.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-5.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-8.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
42.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 28, 2026$0.05$0.03+49.0%
Q1 2026Apr 28, 2026$0.01$0.01+73.0%
Q4 2025Feb 17, 2026$0.06$0.04+50.0%
Q3 2025Oct 28, 2025$0.03$0.02+50.0%
Next earningsTue, Oct 27·consensus EPS $0.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$201.7M+11.2%45.6%-4.8%$0.10$11.7M
Q1 FY26$186.7M+11.1%43.3%-9.8%$-0.65$-13.1M
Q4 FY25$190.2M+10.6%39.8%-5.9%$-0.38$-6.5M
Q3 FY25$187.8M+11.9%42.8%-14.4%$-1.05$570K

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$804.2M$801.0M – $805.8M$0.18$0.16 – $0.199
FY27$884.8M$882.9M – $888.6M$0.34$0.30 – $0.399
FY28$965.6M$952.3M – $977.2M$0.47$0.29 – $0.786
FY29$1.0B$1.0B – $1.0B$0.69$0.68 – $0.704
FY30$1.1B$1.1B – $1.1B$0.81$0.80 – $0.823

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.94%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+58.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 23.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today5.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.755-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 4Greg D AunanChief Accounting Officer20.0K sh$321KSellJun 15Lynn A. TetraultDirector5.3K sh$59KSellJun 9Lynn A. TetraultDirector5.3K sh$60K
+ 30 other (13 exempts · 9 awards · 8 inkinds) in window

See when $NEO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 118-K — Item 5.02: Officer or director change
AI summary

NeoGenomics (NEO) filed an 8-K on August 12, 2026 (event date August 7) under Item 5.02, specifically reporting the departure of an officer. The excerpt is the cover page; the departing officer's identity and circumstances are in the body. NeoGenomics is a specialty oncology diagnostics laboratory company. Senior departures in clinical diagnostics can signal strategic pivots, cost restructuring, or leadership transitions.

8-K/APress release / Reg FD (amended)Jul 228-K/A — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

NEO (NEO) filed a 8-K/A on 2026-07-22. 01, which incorrectly referred to the date “June 20, 2026.” The correct date in each instance is July 20, 2026, consistent with the date of the earliest event reported set forth on the cover page of the Original Form 8-K and the date of the press release furnished as Exhibit 99.1 to the Original Form 8-K. This Amendment is being filed solely to cor Materiality depends on the specific content of this filing.

8-KPress release / Reg FDJul 208-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

NEO (NEO) filed an 8-K under Reg FD (Item 7.01) on 2026-07-20, posting a press release to its website or furnishing it to the SEC. On June 20, 2026, NeoGenomics, Inc. (the “Company”) issued a press release in connection with the settlement agreement described in Item 8.01 below. The information in Item 7.01 of this Current Report and in Exhibit 99.1 attached hereto is being furn This is an informational disclosure furnished (not filed) and does not create new liability under the Exchange Act. Materiality depends on the content of the presentation.

3New insider — initial holdingsJun 253
AI summary

An insider (Amount or Number of Shares Explanation of Responses: Remarks:) at NEO (NEO) filed a Form 3 on 2026-06-25 reporting initial or updated beneficial ownership. This is a routine insider reporting disclosure required within 10 days of becoming a 10%+ holder or new officer/director. It has limited standalone market impact but establishes the baseline for tracking future insider transactions.

8-KOfficer or director changeJun 258-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

NEO (NEO) disclosed a leadership departure/resignation of Board from nine to ten in an 8-K filed on 2026-06-25. On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately. Ms. Starrett will serve as a member of the This is largely an administrative personnel disclosure with limited direct financial impact.

8-KMaterial agreementJun 228-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 3.02: Unregistered equity sale · Item 8.01: Other event
AI summary

NEO (NEO) entered into a material indenture valued at $275.0 million, $41.25 million, $316.25 million on 2026-06-22. Indenture and Notes On June 22, 2026, NeoGenomics, Inc. (the “Company”) completed its previously announced offering of $275.0 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2032 (the “Initial Notes”). On June 17, 2026, the initial purchasers in such offering exercised their option to purchase an additional $41.25 millio. Additional items: 2.03, 3.02, 8.01. This is a material event requiring 8-K disclosure.

8-KOfficer or director changeMay 228-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 18 other (8 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 routine 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212globenewswire.com·2d agoOmada Health (NASDAQ:OMDA) and NeoGenomics (NASDAQ:NEO) Head-To-Head Contrastdefenseworld.net·4d agoNeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conferencedefenseworld.net·9d agoNeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conferencemarketbeat.com·9d agoNeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Resultsglobenewswire.com·14d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$A$GRAL$NTRA$ILMN$TMO$DHR$GH$BLLN
Voices on X · top 6 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport